A randomized, double-blind, multicenter, placebo-controlled study to compare the safety and tolerability of an oral buffered solution of alendronate sodium [alendronic acid] 70 mg once-weekly versus placebo for the treatment of osteoporosis in postmenopausal women

Trial Profile

A randomized, double-blind, multicenter, placebo-controlled study to compare the safety and tolerability of an oral buffered solution of alendronate sodium [alendronic acid] 70 mg once-weekly versus placebo for the treatment of osteoporosis in postmenopausal women

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Alendronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Nov 2009 Actual end date (Mar 2004) and actual number of patients (454) added as reported by ClinicalTrials.gov.
    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top